1. Home
  2. CCO vs PHAT Comparison

CCO vs PHAT Comparison

Compare CCO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCO
  • PHAT
  • Stock Information
  • Founded
  • CCO 1995
  • PHAT 2018
  • Country
  • CCO United States
  • PHAT United States
  • Employees
  • CCO N/A
  • PHAT N/A
  • Industry
  • CCO Advertising
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCO Consumer Discretionary
  • PHAT Health Care
  • Exchange
  • CCO Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • CCO 735.6M
  • PHAT 769.0M
  • IPO Year
  • CCO 2005
  • PHAT 2019
  • Fundamental
  • Price
  • CCO $1.35
  • PHAT $11.70
  • Analyst Decision
  • CCO Hold
  • PHAT Strong Buy
  • Analyst Count
  • CCO 5
  • PHAT 5
  • Target Price
  • CCO $1.78
  • PHAT $16.40
  • AVG Volume (30 Days)
  • CCO 3.7M
  • PHAT 1.3M
  • Earning Date
  • CCO 11-06-2025
  • PHAT 11-06-2025
  • Dividend Yield
  • CCO N/A
  • PHAT N/A
  • EPS Growth
  • CCO N/A
  • PHAT N/A
  • EPS
  • CCO 0.04
  • PHAT N/A
  • Revenue
  • CCO $1,538,895,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • CCO $6.16
  • PHAT $213.11
  • Revenue Next Year
  • CCO $4.01
  • PHAT $91.84
  • P/E Ratio
  • CCO $30.92
  • PHAT N/A
  • Revenue Growth
  • CCO 31.61
  • PHAT 1049.82
  • 52 Week Low
  • CCO $0.81
  • PHAT $2.21
  • 52 Week High
  • CCO $1.69
  • PHAT $19.50
  • Technical
  • Relative Strength Index (RSI)
  • CCO 44.75
  • PHAT 50.37
  • Support Level
  • CCO $1.41
  • PHAT $10.33
  • Resistance Level
  • CCO $1.59
  • PHAT $12.97
  • Average True Range (ATR)
  • CCO 0.08
  • PHAT 0.89
  • MACD
  • CCO -0.02
  • PHAT -0.11
  • Stochastic Oscillator
  • CCO 5.65
  • PHAT 45.41

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: